Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

• Status: Completed
• Trial end date: 2009-05-13
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure

• May or may not be receiving an alternative and/or additional drug treatment